What traders are saying

Join the conversation. Discover trade ideas, share insights, and see how others read the market.

6 days ago

Bearish outlook , but there´s some hope while above 200 weekly MA

come on guys.. it's called price elasticity. you can't raise prices to a point where demand drops.. and people go for cheaper products. that type of brand switching has a ratchet effect.. it's costly to get those customers back once they're gone. I'd rather take a hit from increase costs than take a hit from decreasing demand.. wouldn't you?

kinn64

what's the problem here? strong company, lots of products.. good t a m.. is the CEO dropping the ball?

moonypto

Abbott is buying Exact Sciences for $21 billion, mainly to take over Cologuard, one of the strongest and most reliable at-home cancer screening products on the market. Exact brings in more than $2 billion a year with steady double-digit growth, and Abbott wants that recurring, high-margin diagnostics revenue in its portfolio.

With Abbott’s global distribution and brand power, Cologuard can reach a much larger audience and potentially expand into other cancer screening categories Exact has been developing. The deal should lift Abbott’s diagnostics revenue above $12 billion annually once it closes in 2026.

This move fits a broader trend in healthcare: big companies are buying proven, cash-generating products instead of sinking money into risky R&D. Abbott has the financial strength to keep doing these kinds of acquisitions, backed by low leverage and strong free cash flow.